SectionsMy IBDMy ProductsRecently SearchedTechnologyLicensingALLISON GATLIN05:25 PM ET 09/04/2026Novartis (NVS) said late Friday its Ionis Pharmaceuticals (IONS)-partnered Lp(a) blocker, pelacarsen, failed in Phase 3 testing. The results sent Novartis and Ionis stocks tumbling in after-hours action. Lp(A), or lipoprotein A, is an emerging cardiovascular marker. Companies are working to lower the cholesterol-carrying particle in the blood. Unlike LDL cholesterol and triglycerides, diet and exercise do little to impact…Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8INVESTING RESOURCESTake a Trial TodayGet instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!IBD VideosGet market updates, educational videos, webinars, and stock analysis.Get StartedLearn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content.